Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Plenary Session:  Price & Value

2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

covers in REAL TIME

2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA

 In Attendance, steaming LIVE using Social Media

Aviva Lev-Ari, PhD, RN

Editor-in-Chief

http://pharmaceuticalintelligence.com

Director & Founder

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

https://www.massbio.org/events/2016-massbio-annual-meeting-1120

2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta, Cambridge MA

http://pharmaceuticalintelligence.com/2016/03/02/2016-massbio-annual-meeting-03312016-800-am-04012016-300-pm-royal-sonesta-cambridge-ma/

Plenary Sessions 

Price & Value 

• Katrine Bosley, CEO, Editas

1. The concept evolution: Capitation for DIabetes,
2. not every patient benefit the same treatment not only drug
3. health benefit, side efffect, how to make Patient happier
4. Genetic Medicine: long term benefit vs drug
5. Investment in innovations will benefit by Country , subsidies are differential
6. HCV is a 12 week therapy, very expensive Healthcare system’s benefit from HCV is spectacular in saving cost of treating HCV patients
7. Vaccine has the highest value of al drugs
8. Alzheimer’s Medicine will be widely accepted when proven outcomes
9. Economics of the Disease: Understanding of cost
10. The dream: Treat disease in a meaningful way, engaging in enabling cure

• Jeff Elton, Managing Director, Global Life Sciences Management Consulting, Predictive Health Intelligence, Accenture (Moderator)

1. Unit of exchange
2. strategy to augment response
3.  Gaps to bridge
4. business to business process
5. Transperancy does not solve the Value of Healthcare to patients, it is only one dimension

• John Glasspool, Executive Vice President and Head of Corporate Strategy and Customer Operations, Baxalta

1. Subpopulation like in Epidiemology
2. Standard of care for this Patient – variable around the World
3. consumer paid – Brazil, national coverage in Europe, Insurange coverage in the US
4. Clinical Outcome minus the Costs, risk sharing, societal benefits
5. Utility, threshold, different for various patient populations
6. Contracting: EMR and how to Capture Outcomes
7. Value – how it is derived, demonstrate the value is an obligation
8. what is needed to prove efficacy
9. Obesity drug requires for approval — requires a behavior modification
10. Efficacy moves to Effectiveness
11. evolution decision made by individual vs Group decision making

• Peter Neumann, Director of the Center for the Evaluation of Value and Risk in Health, Tufts University

1. Information on Value and justification for drug price, Turned on its Head Value-based Pricing, paid by value been achieved,
2. value framework and at different stage of acceptance
3. Innovative Value-based Contracting: Pay based on realized outcomes
4. Data  Sciences vs Biological Sciences in ten years it will be the Mathematician Not the Physician to bring the understanding – Measure, convincing
5. Demonstrate Value is beyond evidence